Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 43 |
| Active Pipeline (Recruiting Now) | 22 (10) |
| Completed vs Stopped Early | 19 / 2 (4.7%) |
| Median Closed Actual Enrollment | 40 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Universitätsklinikum Ulm | Ulm | 11 |
| Medizinische Hochschule Hannover | Hanover | 10 |
| Universitätsklinikum Leipzig | Leipzig | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06856837 | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR | Phase II | RECRUITING |
| NCT07387198 | Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | Phase II | RECRUITING |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma | Phase II | RECRUITING |
| NCT07176312 | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) P | Phase II | RECRUITING |
| NCT07260175 | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.